Stratos Wealth Partners LTD. Sells 242 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Stratos Wealth Partners LTD. lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,651 shares of the medical equipment provider’s stock after selling 242 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zimmer Biomet were worth $789,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Private Trust Co. NA raised its holdings in Zimmer Biomet by 14.6% during the 2nd quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock valued at $98,000 after buying an additional 137 shares during the last quarter. Applied Finance Capital Management LLC purchased a new position in shares of Zimmer Biomet in the second quarter valued at about $445,000. Nordea Investment Management AB raised its stake in shares of Zimmer Biomet by 7.3% during the second quarter. Nordea Investment Management AB now owns 17,839 shares of the medical equipment provider’s stock valued at $1,628,000 after acquiring an additional 1,210 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in shares of Zimmer Biomet by 0.5% during the second quarter. New York State Teachers Retirement System now owns 157,785 shares of the medical equipment provider’s stock worth $14,392,000 after purchasing an additional 851 shares during the period. Finally, Generali Asset Management SPA SGR grew its stake in shares of Zimmer Biomet by 16.9% in the second quarter. Generali Asset Management SPA SGR now owns 14,110 shares of the medical equipment provider’s stock worth $1,287,000 after purchasing an additional 2,042 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. BTIG Research upped their target price on Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective on the stock. Finally, Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Price Performance

ZBH opened at $103.87 on Thursday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The company has a market cap of $20.58 billion, a price-to-earnings ratio of 25.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67. The stock has a fifty day simple moving average of $101.83 and a two-hundred day simple moving average of $97.72. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.